These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26065226)

  • 1. [The revolution in the treatment of retinal diseases: anti-VEGF treatment at the Assuta Eye Institute].
    Katz G; Zehavi C; Treister G
    Harefuah; 2015 Apr; 154(4):270-3, 278. PubMed ID: 26065226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aflibercept in wet AMD: specific role and optimal use.
    Semeraro F; Morescalchi F; Duse S; Parmeggiani F; Gambicorti E; Costagliola C
    Drug Des Devel Ther; 2013; 7():711-22. PubMed ID: 23990705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of VEGF in diseases of the retina].
    Barquet LA
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Initial experience with aflibercept in the management of patients with wet age-related macular degeneration refractory to ranibizumab and/or bevacizumab].
    Cervera RE; Castro V; Montero J; Torralba C; Gracia A
    Arch Soc Esp Oftalmol; 2014 Jan; 89(1):42-3. PubMed ID: 24269436
    [No Abstract]   [Full Text] [Related]  

  • 7. [Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data].
    Weber M; Sennlaub F; Souied E; Cohen SY; Béhar-Cohen F; Milano G; Tadayoni R
    J Fr Ophtalmol; 2014 Sep; 37(7):566-79. PubMed ID: 25190312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
    Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
    Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.
    Stewart MW
    Mayo Clin Proc; 2012 Jan; 87(1):77-88. PubMed ID: 22212972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National survey of the ophthalmic use of anti-vascular endothelial growth factor drugs in Israel.
    Waisbourd M; Goldstein M; Loewenstein A
    Isr Med Assoc J; 2011 Mar; 13(3):141-6. PubMed ID: 21608333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
    Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fusion Proteins: Aflibercept (VEGF Trap-Eye).
    Sarwar S; Bakbak B; Sadiq MA; Sepah YJ; Shah SM; Ibrahim M; Do DV; Nguyen QD
    Dev Ophthalmol; 2016; 55():282-94. PubMed ID: 26501481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Basic in vitro studies on VEGF inhibition with aflibercept: similarities and differences to other VEGF-binding therapeutic proteins].
    Lang GE; Lang GK; Deissler HL
    Klin Monbl Augenheilkd; 2015 Mar; 232(3):295-302. PubMed ID: 25393440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
    Schmid MK; Bachmann LM; Fäs L; Kessels AG; Job OM; Thiel MA
    Br J Ophthalmol; 2015 Feb; 99(2):141-6. PubMed ID: 25271911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
    Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
    Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted pharmacotherapy of retinal diseases with ranibizumab.
    Campochiaro PA
    Drugs Today (Barc); 2007 Aug; 43(8):529-37. PubMed ID: 17925884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept (Eylea) and diabetic macular oedema. A first-choice VEGF inhibitor in case of marked visual loss.
    Prescrire Int; 2015 Sep; 24(163):207. PubMed ID: 26417628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.
    Julien S; Biesemeier A; Taubitz T; Schraermeyer U
    Br J Ophthalmol; 2014 Jun; 98(6):813-25. PubMed ID: 24457369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
    Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
    Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.